245 related articles for article (PubMed ID: 16989818)
21. Dissimilar interaction of CB1/CB2 with lipid bilayers as revealed by molecular dynamics simulation.
Ramos J; Cruz VL; Martínez-Salazar J; Campillo NE; Páez JA
Phys Chem Chem Phys; 2011 Mar; 13(9):3660-8. PubMed ID: 21173968
[TBL] [Abstract][Full Text] [Related]
22. Regulation of opioid and cannabinoid receptor genes in human neuroblastoma and T cells by the epigenetic modifiers trichostatin A and 5-aza-2'-deoxycytidine.
Börner C; Martella E; Höllt V; Kraus J
Neuroimmunomodulation; 2012; 19(3):180-6. PubMed ID: 22262103
[TBL] [Abstract][Full Text] [Related]
23. Pharmacological evaluation of LH-21, a newly discovered molecule that binds to cannabinoid CB1 receptor.
Chen RZ; Frassetto A; Lao JZ; Huang RR; Xiao JC; Clements MJ; Walsh TF; Hale JJ; Wang J; Tong X; Fong TM
Eur J Pharmacol; 2008 Apr; 584(2-3):338-42. PubMed ID: 18336811
[TBL] [Abstract][Full Text] [Related]
24. 3D-QSAR studies of arylpyrazole antagonists of cannabinoid receptor subtypes CB1 and CB2. A combined NMR and CoMFA approach.
Chen JZ; Han XW; Liu Q; Makriyannis A; Wang J; Xie XQ
J Med Chem; 2006 Jan; 49(2):625-36. PubMed ID: 16420048
[TBL] [Abstract][Full Text] [Related]
25. Cannabinoid receptors in invertebrates.
McPartland JM; Agraval J; Gleeson D; Heasman K; Glass M
J Evol Biol; 2006 Mar; 19(2):366-73. PubMed ID: 16599912
[TBL] [Abstract][Full Text] [Related]
26. CB1 and CB2 cannabinoid receptor expression during development and in epileptogenic developmental pathologies.
Zurolo E; Iyer AM; Spliet WG; Van Rijen PC; Troost D; Gorter JA; Aronica E
Neuroscience; 2010 Sep; 170(1):28-41. PubMed ID: 20621164
[TBL] [Abstract][Full Text] [Related]
27. CB2 cannabinoid receptor mediation of antinociception.
Ibrahim MM; Rude ML; Stagg NJ; Mata HP; Lai J; Vanderah TW; Porreca F; Buckley NE; Makriyannis A; Malan TP
Pain; 2006 May; 122(1-2):36-42. PubMed ID: 16563625
[TBL] [Abstract][Full Text] [Related]
28. Cannabinoid receptors 1 and 2 (CB1 and CB2), their distribution, ligands and functional involvement in nervous system structures--a short review.
Svízenská I; Dubový P; Sulcová A
Pharmacol Biochem Behav; 2008 Oct; 90(4):501-11. PubMed ID: 18584858
[TBL] [Abstract][Full Text] [Related]
29. Neuropsychobiological evidence for the functional presence and expression of cannabinoid CB2 receptors in the brain.
Onaivi ES
Neuropsychobiology; 2006; 54(4):231-46. PubMed ID: 17356307
[TBL] [Abstract][Full Text] [Related]
30. Cannabinoids modulate cell survival in embryoid bodies.
Nones J; Spohr TC; Furtado DR; Sartore RC; Paulsen BS; Guimarães MZ; Rehen SK
Cell Biol Int; 2010 Mar; 34(4):399-408. PubMed ID: 19947926
[TBL] [Abstract][Full Text] [Related]
31. 1,2,3-Triazole derivatives as new cannabinoid CB1 receptor antagonists.
Hou DR; Alam S; Kuan TC; Ramanathan M; Lin TP; Hung MS
Bioorg Med Chem Lett; 2009 Feb; 19(3):1022-5. PubMed ID: 19095444
[TBL] [Abstract][Full Text] [Related]
32. Binding thermodynamics at the human cannabinoid CB1 and CB2 receptors.
Merighi S; Simioni C; Gessi S; Varani K; Borea PA
Biochem Pharmacol; 2010 Feb; 79(3):471-7. PubMed ID: 19766600
[TBL] [Abstract][Full Text] [Related]
33. Allosteric and orthosteric pharmacology of cannabidiol and cannabidiol-dimethylheptyl at the type 1 and type 2 cannabinoid receptors.
Tham M; Yilmaz O; Alaverdashvili M; Kelly MEM; Denovan-Wright EM; Laprairie RB
Br J Pharmacol; 2019 May; 176(10):1455-1469. PubMed ID: 29981240
[TBL] [Abstract][Full Text] [Related]
34. Novel benzimidazole derivatives as selective CB2 agonists.
Pagé D; Balaux E; Boisvert L; Liu Z; Milburn C; Tremblay M; Wei Z; Woo S; Luo X; Cheng YX; Yang H; Srivastava S; Zhou F; Brown W; Tomaszewski M; Walpole C; Hodzic L; St-Onge S; Godbout C; Salois D; Payza K
Bioorg Med Chem Lett; 2008 Jul; 18(13):3695-700. PubMed ID: 18522867
[TBL] [Abstract][Full Text] [Related]
35. Design, synthesis and biological evaluation of piperazine analogues as CB1 cannabinoid receptor ligands.
Song KS; Lee SH; Chun HJ; Kim JY; Jung ME; Ahn K; Kim SU; Kim J; Lee J
Bioorg Med Chem; 2008 Apr; 16(7):4035-51. PubMed ID: 18243711
[TBL] [Abstract][Full Text] [Related]
36. [The endocannabinoid system as a novel target for the treatment of liver fibrosis].
Teixeira-Clerc F; Julien B; Grenard P; Tran Van Nhieu J; Deveaux V; Hezode C; Mallat A; Lotersztajn S
Pathol Biol (Paris); 2008 Feb; 56(1):36-8. PubMed ID: 17412522
[TBL] [Abstract][Full Text] [Related]
37. Expression and function of cannabinoid receptors CB1 and CB2 and their cognate cannabinoid ligands in murine embryonic stem cells.
Jiang S; Fu Y; Williams J; Wood J; Pandarinathan L; Avraham S; Makriyannis A; Avraham S; Avraham HK
PLoS One; 2007 Jul; 2(7):e641. PubMed ID: 17653268
[TBL] [Abstract][Full Text] [Related]
38. Synthesis and pharmacology of 11-nor-1-methoxy-9-hydroxyhexahydrocannabinols and 11-nor-1-deoxy-9-hydroxyhexahydrocannabinols: new selective ligands for the cannabinoid CB2 receptor.
Marriott KS; Huffman JW; Wiley JL; Martin BR
Bioorg Med Chem; 2006 Apr; 14(7):2386-97. PubMed ID: 16321538
[TBL] [Abstract][Full Text] [Related]
39. Predominant CB2 receptor expression in endothelial cells of glioblastoma in humans.
Schley M; Ständer S; Kerner J; Vajkoczy P; Schüpfer G; Dusch M; Schmelz M; Konrad C
Brain Res Bull; 2009 Jun; 79(5):333-7. PubMed ID: 19480992
[TBL] [Abstract][Full Text] [Related]
40. Development of CoMFA and CoMSIA models of affinity and selectivity for indole ligands of cannabinoid CB1 and CB2 receptors.
De Freitas GB; da Silva LL; Romeiro NC; Fraga CA
Eur J Med Chem; 2009 Jun; 44(6):2482-96. PubMed ID: 19249138
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
